Jan 23, 2026 02:50PM DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event

Dec 16, 2025 10:31AM Jupiter Neurosciences receives FDA clearance for Parkinson's trial

Dec 2, 2025 04:15PM Jupiter Neurosciences to Participate in NobleCon21

Oct 27, 2025 08:30AM Jupiter Neurosciences secures up to $20 million financing deal

Jul 23, 2025 08:00AM Jupiter Neurosciences reports 9x bioavailability boost for resveratrol drug

Jul 10, 2025 04:05PM Jupiter Neurosciences regains NASDAQ compliance after stock price recovery

Jun 30, 2025 03:15PM Jupiter Neurosciences (JUNS) Showcases Nugevia PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery

Jun 27, 2025 08:02AM Jupiter Neurosciences (JUNS) Unveils Nugevia GLO

Jun 9, 2025 07:02AM Jupiter Neurosciences (JUNS) Launches Nugevia

Apr 8, 2025 08:06AM Jupiter Neurosciences (JUNS) Highlights Upcoming Milestones in Shareholder Letter

Mar 7, 2025 11:10AM Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 4, 2025 08:00AM Jupiter Neurosciences (JUNS) and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

Feb 4, 2025 09:25AM Jupiter Neurosciences (JUNS) Addresses Market Volatility

Feb 3, 2025 08:01AM Jupiter Neurosciences (JUNS) Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

Jan 30, 2025 08:02AM Jupiter Neurosciences (JUNS) Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

Jan 13, 2025 08:10AM Jupiter Neurosciences (JUNS) Announces Strategic Focus on NLRP3 Pathway in Future JOTROL Trials

Dec 19, 2024 10:28AM Greenridge Capital Starts Jupiter Neurosciences (JUNS) at Buy

Sep 4, 2024 06:18AM Jupiter Neurosciences (JUNS) Files for 2.75M Share IPO at $4-$5/sh